This site is intended for healthcare professionals


Select the drug indication to add to your list

Inborn errors of metabolism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:


Generic Name and Formulations:
Eliglustat 84mg; hard-gel caps.

Sanofi Genzyme Company

Therapeutic Use:

Indications for CERDELGA:

Long-term treatment of adults with Gaucher disease type 1 who are CYP2D6 extensive, intermediate, or poor metabolizers as detected by an FDA-cleared test. Limitations of use: CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations for a therapeutic effect. No dosage recommendation for CYP2D6 indeterminate metabolizers.


Swallow whole with water. Extensive and intermediate metabolizers: 84mg twice daily. Poor metabolizers: 84mg once daily; monitor. Extensive and intermediate metabolizers taking strong or moderate CYP2D6 inhibitors (eg, paroxetine, terbinafine); or extensive metabolizers taking strong or moderate CYP3A inhibitors (eg, ketoconazole, fluconazole): reduce to 84mg once daily. Currently on imiglucerase, velaglucerase alfa, or taligucerase alfa: administer eliglustat 24hrs after last dose of the previous enzyme replacement therapy.


Not established.


Extensive or intermediate metabolizers taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor. Intermediate or poor metabolizers taking a strong CYP3A inhibitor (eg, ketoconazole).


Determine CYP2D6 genotype using an FDA-cleared test. Pre-existing cardiac disease (CHF, recent MI, bradycardia, heart block, ventricular arrhythmia), long QT syndrome: not recommended. Moderate-to-severe renal impairment, ESRD, hepatic impairment, cirrhosis: not recommended. Pregnancy (Cat.C). Nursing mothers: not recommended.


See Contraindications. Increased risk of arrhythmias with concomitant CYP2D6 and CYP3A inhibitors; adjust dose based on metabolizer status (see full labeling). Avoid grapefruit or grapefruit juice. Concomitant Class IA (eg, quinidine, procainamide) and Class III (eg, amiodarone, sotalol) antiarrhythmics, CYP3A inducers (eg, rifampin, carbamazepine, phenobarbital, phenytoin, St. John’s wort): not recommended. Concomitant digoxin; reduce digoxin dose by 30% and monitor. Potentiates P-gp substrates (eg, phenytoin, colchicine, dabigatran etexilate) or CYP2D6 substrates (eg, metoprolol, tricyclic antidepressants, phenothiazines); monitor and consider reducing dose of these drugs.

Pharmacological Class:

Glucosylceramide synthase inhibitor.

Adverse Reactions:

Fatigue, headache, nausea, diarrhea, back pain, pain in extremities, upper abdominal pain; ECG changes, arrhythmias.

How Supplied:

Blister card (14 caps)—1, 4

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.

Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Groin swelling - red flag symptomsExternal web site

This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...

0.50 Credits
Red flags

Erectile dysfunction - red flag symptomsExternal web site

This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...

0.50 Credits
Red flags

Headache - red flag symptomsExternal web site

Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Basal cell carcinoma: clinical reviewExternal web site

In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...

1.50 Credits
Clinical Review

Cardiomyopathy: clinical reviewExternal web site

This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...

1.50 Credits
Clinical Review

Parkinson's disease: clinical reviewExternal web site

Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »